Market Closed -
Euronext Paris
16:35:12 04/07/2024 BST
5-day change
1st Jan Change
155
EUR
+1.97%
+0.52%
-35.30%
Sartorius Stedim Biotech SA: DECLARATION RELATIVE AU NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
July 02, 2024 at 01:57 pm
Sartorius Stedim Biotech SA: DECLARATION RELATIVE AU NOMBRE D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
Issuer
SARTORIUS STEDIM BIOTECH
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION RELATIVE AU NOMBRE D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL02-Juil-2024 / 14:53 CET/CEST
Information réglementaire transmise par EQS Group.
Le contenu de ce communiqué est de la responsabilité de l'émetteur.
Sartorius Stedim Biotech S.A. - 13781 Aubagne Cedex, France
DECLARATION RELATIVE
AU NOMBRE D'ACTIONS ET DE DROITS DE VOTE
COMPOSANT LE CAPITAL SOCIAL
Article L 233-8-II du Code de commerce
et article 223-6 du règlement général de l'AMF
Dénomination de l'émetteur
SARTORIUS STEDIM BIOTECH SA
CS 91051
Z. I. Les Paluds
Avenue de Jouques
13781 Aubagne Cedex
Date d'arrêté
des informations
Nombre total d'actions composant
le capital social
Nombre total de droits de vote théoriques, inclus actions auto-détenues par la Société
Nombre total
de droits de vote nets
30 Juin 2024
97 330 405
165 575 822
165 528 510
Fichier PDF dépôt réglementaire
Document : DECLARATION RELATIVE AU NOMBRE D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
Langue :
Français
Entreprise :
Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Téléphone :
+33 44 284 5600
E-mail :
sartorius.presse@sartorius.com
Internet :
www.sartorius-stedim.com
ISIN :
FR0013154002
Ticker Euronext :
DIM
Catégorie AMF :
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
EQS News ID :
1938119
Fin du communiqué
EQS News-Service
1938119 02-Juil-2024 CET/CEST
OJPQBMUISOXGJWSPEGROJEUH_20240630_SSB_IR_Declaration_voting_rights_fr.pdf
Source
Sartorius Stedim Biotech SA
Company Name
SARTORIUS STED BIO, SARTORIUS STEDIM BIOTECH
ISIN
FR0013154002, FR0013154002
Disclaimer
Sartorius Stedim Biotech SA published this content on
02 July 2024 and is solely responsible for the information contained therein. Distributed by
Public , unedited and unaltered, on
02 July 2024 12:56:04 UTC .
Oddo BHF Upgrades Sartorius Stedim Biotech to Outperform from Neutral, Lowers PT
07-04
MT
Sartorius recovers 15 percent from annual low - Oddo recommendation
07-04
DP
Sartorius further stabilized
07-03
DP
SARTORIUS STEDIM BIOTECH : Gets a Neutral rating from Barclays
06-27
ZD
The same old winners
06-27
Sartorius stabilizes after previous day's price slide
06-20
DP
Sartorius on the downswing again - low since 2020 is approaching
06-19
DP
SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%)
06-03
Sartorius sinks again towards year low
05-16
DP
Transcript : Sartorius Stedim Biotech S.A., Sartorius Aktiengesellschaft - Analyst/Investor Day
05-16
Certain Shares of Sartorius Stedim Biotech S.A. are subject to a Lock-Up Agreement Ending on 8-MAY-2024.
05-07
CI
SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating
04-23
ZD
Sartorius Stedim: in the red with brokerage comments
04-22
CF
UBS Cuts Sartorius Stedim Biotech PT, Maintains at Neutral
04-22
MT
SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss
04-22
SARTORIUS STEDIM : UBS reduces target price
04-22
CF
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...
04-18
Transcript : Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024
04-18
Transcript : Sartorius Aktiengesellschaft, Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024
04-18
Sartorius and subsidiary Stedim under pressure after weak figures
04-18
DP
Europe in the green, corporate results hailed
04-18
RE
Sartorius Stedim: Quarterly EPS more than halved
04-18
CF
Sartorius Stedim Biotech S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-18
CI
Sartorius Stedim Biotech Records Lower Q1 Attributable Net Profit, Sales Revenue
04-18
MT
Transcript : Sartorius Stedim Biotech S.A. - Shareholder/Analyst Call
03-26
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically.
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
More about the company
Average target price
245.9
EUR
Spread / Average Target
+58.71%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1